Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. Freelancer and Factor Therapeutics are examples of many potential outperformers that analysts are bullish on. The list I've put together below are of stocks that compare favourably on all criteria, which potentially makes them a good investment if you believe the growth has not already been reflected in the share price.
Freelancer Limited ( ASX:FLN )
Freelancer Limited operates a freelancing and crowdsourcing marketplace in Australia. Started in 2009, and currently run by Robert Barrie, the company now has 390 employees and with the stock's market cap sitting at AUD A$219.29M, it comes under the small-cap stocks category.
Extreme optimism for FLN, as market analysts projected an outstanding earnings growth, which is expected to more than double, supported by a double-digit sales growth of 19.85%. Though some cost-cutting activities may artificially inflate margins, it appears that this isn't solely the case here, as profit growth is also coupled with high top-line expansion. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 19.78%. FLN's bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Should you add FLN to your portfolio? Other fundamental factors you should also consider can be found here .
Factor Therapeutics Limited ( ASX:FTT )
Factor Therapeutics Limited, a clinical stage biotechnology company, develops and commercializes treatments for wound care and healing in Australia and Europe. Factor Therapeutics is currently run by Nigel Johnson. The company currently has a market cap of AUD A$33.37M, putting it in the small-cap category
FTT's projected future profit growth is an exceptional triple-digit, with an underlying triple-digit growth from its revenues expected over the upcoming years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn't artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. We see this bottom-line expansion directly benefiting shareholders, with expected positive return on equity of 18.45%. FTT's bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Should you add FTT to your portfolio? I recommend researching its fundamentals here .
Bellamy's Australia Limited ( ASX:BAL )
Bellamy's Australia Limited produces and markets organic foods and formula products for babies, toddlers, and young children. Established in 2004, and now led by CEO Andrew Cohen, the company size now stands at 46 people and with the company's market capitalisation at AUD A$2.09B, we can put it in the mid-cap category.
Driven by the positive double-digit sales growth of 48.92% over the next few years, BAL is expected to deliver an excellent earnings growth of 38.72%. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn't artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. We see this bottom-line expansion directly benefiting shareholders, with expected return on equity coming in at a notable 26.90%. BAL's impressive outlook on all aspects makes it a worthy company to spend more time to understand. Want to know more about BAL? Have a browse through its key fundamentals here .
For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.
